Not Yet Recruiting
Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
NCT06956092
- Conditions
- B Cell Lymphoma (BCL), Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- The First Affiliated Hospital of Zhengzhou University, Department of Oncology Zhengzhou, Henan, China